Business
Akili ADHD Treatment Now Available in US
Akili ADHD Treatment Now Available in US.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 4644K\n PureTech Health PLC\n 22 April 2020\n \n \n \n \n 22 April 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity Akili\n \n \n Announces \n \n \n ENDEAVORTM\n \n \n Digital\n Attention Treatment\n \n is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA's COVID-19 Enforcement Discretion Guidance\n \n \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech,\" or the \"Company\") \n is pleased to note that its Founded Entity, Akili, today announced \n that ENDEAVORTM (AKL-T01) is now available in the US for use by children with attention deficit hyperactivity disorder (ADHD) and their families. Akili is pursuing US Food and Drug Administration (FDA) clearance of ENDEAVOR as a prescription treatment for use in paediatric ADHD. In parallel, the current release of ENDEAVOR is in response to new \n \n \n guidance\n \n \n from FDA recognising the need for access to certain low-risk clinically-validated digital health devices for psychiatric conditions, including ADHD during the COVID-19 pandemic. Akili is releasing ENDEAVOR to families with children diagnosed with ADHD and struggling with chronic attention issues. ENDEAVOR is downloaded from the App Store, and a separate companion app is also available to help parents track and better understand changes in their child's behaviour. For a limited time, Akili is providing access to ENDEAVOR to those who qualify at no cost.\n \n \n \n \n \n Daphne Zohar, founder and chief executive officer of PureTech, said: \"The launch of Akili's ENDEAVOR is a milestone for the field of digital medicine and for the millions of children with ADHD. \n When we founded Akili, the PureTech team envisioned an effective and evidence-based, non-pharmacological treatment for ADHD that physicians and parents would be comfortable supporting and children would enjoy using\n . We believe the large body of data generated to date supports this vision and distinguishes ENDEAVOR as a first of its kind, non-pharmaceutical digital treatment to help children address \n inattentiveness, one of the most pervasive symptoms of ADHD. \n \n \n \n \n \n \"Today's launch also highlights the importance of telehealth, a broad theme carried across several of our Founded Entities. Remote tre...